Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the International Prognostic Scoring System

Journal of Clinical Oncology

Volumn 29, Issue 15, 2011, Pages 1963-1970

  Schanz, Julie ^{a,b,c,d,e,f,g,h,i,j}   Steidl, Christian ^{a,b,c,d,e,f,g,h,i,j}   Fonatsch, Christa ^{a,b,c,d,e,f,g,h,i,j}   Pfeilstöcker, Michael ^{a,b,c,d,e,f,g,h,i,j}   Nösslinger, Thomas ^{a,b,c,d,e,f,g,h,i,j}   Tuechler, Heinz ^{a,b,c,d,e,f,g,h,i,j}   Valent, Peter ^{a,b,c,d,e,f,g,h,i,j}   Hildebrandt, Barbara ^{a,b,c,d,e,f,g,h,i,j}   Giagounidis, Aristoteles ^{a,b,c,d,e,f,g,h,i,j}   Aul, Carlo ^{a,b,c,d,e,f,g,h,i,j}   Lübbert, Michael ^{a,b,c,d,e,f,g,h,i,j}   Stauder, Reinhard ^{a,b,c,d,e,f,g,h,i,j}   Krieger, Otto ^{a,b,c,d,e,f,g,h,i,j}   Garcia Manero, Guillermo ^{a,b,c,d,e,f,g,h,i,j}   Kantarjian, Hagop ^{a,b,c,d,e,f,g,h,i,j}   Germing, Ulrich ^{a,b,c,d,e,f,g,h,i,j}   Haase, Detlef ^{a,b,c,d,e,f,g,h,i,j}   Estey, Elihu ^{a,b,c,d,e,f,g,h,i,j}  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c Johannes Hospital   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^h ELISABETHINEN HOSPITAL   (Austria)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j SEATTLE CANCER CARE ALLIANCE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMIFOSTINE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CYCLOSPORIN; HEMOPOIETIC GROWTH FACTOR; IMMUNOMODULATING AGENT; IRON CHELATING AGENT; LENALIDOMIDE; THALIDOMIDE; VALPROIC ACID;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLAST CELL; BLOOD TRANSFUSION; BONE MARROW; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL COUNT; CHROMOSOME; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; DATA BASE; FEMALE; HAZARD RATIO; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLAST CRISIS; CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RISK ASSESSMENT;

EID: 79956318358     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.3978     Document Type: Article

References (24)

1. Haase D, Feuring-Buske M, Schäfer C, et al: Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117. Leukemia 11:674-679, 1997 (Pubitemid 27241246)
2. Mufti GJ, Stevens JR, Oscier DG, et al: Myelodysplastic syndromes: A scoring system with prognostic significance. Br J Haematol 59:425-433, 1985 (Pubitemid 15132943)
3. Sanz GF, Sanz MA, Vallespí T, et al: Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients. Blood 74:395-408, 1989 (Pubitemid 19187457)
4. Aul C, Gattermann N, Heyll A, et al: Primary myelodysplastic syndromes: Analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 6:52-59, 1992
5. Morel P, Hebbar M, Lai JL, et al: Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases. Leukemia 7:1315-1323, 1993 (Pubitemid 23291068)
6. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997 (Pubitemid 27132124)
7. Solé F, Luño E, Sanzo C, et al: Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 90: 1168-1178, 2005 (Pubitemid 41375276)
8. Malcovati L, Germing U, Kuendgen A, et al: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503-3510, 2007 (Pubitemid 47315575)
9. Steidl C, Schanz J, Pfeilstöcker M, et al: Growing evidence for an underestimation of poor-risk cytogenetics in the international prognostic scoring system in myelodysplastic syndromes. Clin Leukemia 1:353-356, 2007
10. Schanz J, Estey E, Steidl C, et al: Multivariate analysis suggests that the prognostic impact of poor risk cytogenetics is potentially underestimated in the IPSS. Presented at the American Society of Hematology (ASH) Annual Meeting, Atlanta, GA, December 8-11, 2007
11. Haase D, Germing U, Schanz J, et al: New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood 110:4385-4395, 2007 (Pubitemid 351377805)
12. Mitelman F: ISCN: Guidelines for Cancer Cytogenetics: Supplement to an International System for Human Cytogenetic Nomenclature. Basel, Switzerland, S. Karger, 1995
13. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199, 1982 (Pubitemid 12073508)
14. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting- Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35:1-39, 1977 (Pubitemid 8018922)
17. Satagopan JM, Ben-Porat L, Berwick M, et al: A note on competing risks in survival data analysis. Br J Cancer 91:1229-1235, 2004 (Pubitemid 39424779)
18. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
19. Germing U, Hildebrandt B, Pfeilstöcker M, et al: Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 19:2223-2231, 2005
20. Kao JM, McMillan A, Greenberg PL: International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol 83:765-770, 2008
21. Garcia-Manero G, Shan J, Faderl S, et al: A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22:538-543, 2008 (Pubitemid 351386723)
22. Kantarjian H, O'Brien S, Ravandi F, et al: Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 113:1351-1356, 2008
23. Valent P, Horny HP, Bennett JM, et al: Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 31:727-736, 2007 (Pubitemid 46855901)
24. Steidl C, Schanz J, LeBeau MM, et al: Coalescence of the German-Austrian and IMRAW Cytogenetic MDS Databases: Modification of Patient Risk Groups. Presented at the American Society of Hematology (ASH) Annual Meeting, Atlanta, GA, December 8-11, 2007